Squarepoint
KROS icon

Squarepoint’s Keros Therapeutics KROS Stock Holding History

Squarepoint’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-100,141
Closed -$1.58M – 4592
2025
Q3 		$1.58M Buy
+100,141
New +$1.48M ﹤0.01% 2290
2025
Q2 		– Sell
-43,984
Closed -$448K – 4783
2025
Q1 		$448K Buy
+43,984
New +$511K ﹤0.01% 3407
2024
Q4 		– Sell
-4,525
Closed -$263K – 5288
2024
Q3 		$263K Sell
4,525
-15,307
-77% -$756K ﹤0.01% 3539
2024
Q2 		$906K Buy
+19,832
New +$1.07M ﹤0.01% 2634
2022
Q4 		– Sell
-19,919
Closed -$749K – 3423
2022
Q3 		$749K Buy
19,919
+2,204
+12% +$76.4K ﹤0.01% 1957
2022
Q2 		$489K Buy
+17,715
New +$777K ﹤0.01% 2026
2021
Q1 		– Sell
-9,035
Closed -$637K – 3373
2020
Q4 		$637K Buy
+9,035
New +$569K ﹤0.01% 1626

Other funds holding KROS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Squarepoint's KROS Position: Q4 2025 in Review

Squarepoint sold out of Keros Therapeutics (KROS) in Q4 2025, closing a stake of 100,141 shares — an estimated $1.58M sold.

Squarepoint first reported a position in KROS in Q4 2020 and held it in 7 quarters. The position peaked at $1.58M in Q3 2025. 166 funds tracked by Wall St. Rank hold KROS as of Q4 2025.

  • Squarepoint reported no remaining Keros Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Squarepoint sold 100,141 Keros Therapeutics shares in Q4 2025, an estimated $1.58M.
  • Squarepoint first reported a position in Keros Therapeutics in Q4 2020 and held it in 7 quarters.
  • Squarepoint's Keros Therapeutics position peaked at $1.58M in Q3 2025.
  • 166 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2025.

Based on Squarepoint's 13F filing for Q4 2025, filed 13 Feb 2026.